The development of specific antibodies against TNF-α will make it possible to reduce the cost of biological drugs in the Basic Table of Medicines and thus, provide access to cutting-edge products (therapeutic antibodies) and therapies to the Mexican and worldwide population.

This project will allow the development of innovative therapeutic antibodies (anti-TNF-α) from Mexico. To substitute with an anti-TNF-α product made in Mexico several of the therapeutic antibodies of the Basic Table of Medications.

In our institution, we have a solid technological platform for the discovery of therapeutic antibodies, which involves a rigorous selection process based on stability, affinity and specificity. This state-of-the-art platform, unique in Mexico, can be used to isolate antibodies for different purposes in the diagnosis and treatment of diseases.

So far we have a set of anti-TNF-α antibodies from ALTHEA Gold Libraries™. Some of these antibodies have neutralizing and blocking capacity against membranal TNF. We have selected a leading antibody that has been improved through affinity optimization processes, with the aim of obtaining an antibody similar to or better than others currently used in the clinic.